Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05886712 · ClinicalTrials.gov registry record · NA

Improving Access to Naloxone to Prevent Opioid Overdose Deaths (SAIA-Naloxone)

A NA study of Overdose and Implementation as Usual, sponsored by RTI International.

Active
Registry status
NA
Development phase
31
Enrollment target
1
Study location

NCT05886712: Active NA study of Overdose and Implementation as Usual, sponsored by RTI International.

NCT05886712 is a NA study of Overdose and Implementation as Usual that is active but no longer recruiting, run by RTI International. The registered enrollment target is 31 participants, below the 263-participant average among 13 other Overdose trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05886712, a NA study of Overdose and Implementation as Usual, is active but no longer recruiting, sponsored by RTI International.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
31 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to compare the effectiveness of a multi-faceted implementation strategy, the Systems Analysis and Improvement Approach for Naloxone (SAIA-N), in syringe service programs (SSPs). The main questions it aims to answer are: * Does SAIA-N improve naloxone distribution (number of doses, number of people receiving naloxone) compared to implementation as usual (IAU)? * What are the costs associated with SAIA-N and how cost-effective is the strategy? SSPs randomized to the SAIA-N arm will participate in the strategy for a period of 12-months during which they will meet 1-2 times each month with a SAIA coach who will assist the SSP in optimizing their naloxone distribution. Researchers will compare SAIA-N to IAU to see if naloxone distribution and costs and cost-effectiveness differ by group.

Primary Outcome

Number of participants screened for naloxone engagement, while accounting for the total number of participants who present for services

Interventions

  • OTHER Naloxone
  • OTHER Usual intervention

Study Locations (1)

California

  • RTI International - Berkeley

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2023-07-01
Est. Completion 2026-06-30
Phase NA
RTI International

45 total trials

What the registry record for NCT05886712 still lists

NCT05886712 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 263-participant average among 13 other Overdose trials with a reported enrollment target (88% lower).

The record links to 2 conditions, with Overdose appearing as the primary indexed condition, and to 2 interventions - of which Naloxone is the first listed.

NCT05886712 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05886712 about?

NCT05886712 is a clinical study titled "Improving Access to Naloxone to Prevent Opioid Overdose Deaths (SAIA-Naloxone)". The goal of this clinical trial is to compare the effectiveness of a multi-faceted implementation strategy, the Systems Analysis and Improvement Approach for Naloxone (SAIA-N), in syringe service programs (SSPs). The main questions it aims to answer are: * Does SAIA-N improve naloxone distribution ...

What is the current status of trial NCT05886712?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 31 participants. The study started on 2023-07-01. Estimated completion is 2026-06-30.

What conditions does trial NCT05886712 study?

This clinical trial studies the following conditions: Overdose, Implementation as Usual.

What interventions are being tested in trial NCT05886712?

The interventions under investigation include: Naloxone (OTHER), Usual intervention (OTHER).

Who is sponsoring clinical trial NCT05886712?

This trial is sponsored by RTI International, which has 45 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05886712 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Overdose

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05886712's enrollment target sits among peer trials

31 11th of 13 higher than 3 of 13 other Overdose trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Overdose trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02932618 · 31 participants · Phase 3

    A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

  • NCT03482297 · 31 participants · Phase 1

    Automated Abdominal Binder for Orthostatic Hypotension

  • NCT04016389 · 31 participants · NA

    FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

  • NCT04211675 · 31 participants · Phase 1

    NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05886712, the US trial registry maintained by the National Library of Medicine. NCT05886712 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.